Efficacy of Oral Ibandronate in Osteoporosis

NCT ID: NCT03186131

Last Updated: 2021-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-12

Study Completion Date

2025-06-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There has been no comparative data between oral ibandronate and oral ibandronate plus active vitamin D

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Ibandronate alone

Monthly Oral Intake of Ibandronate

Group Type ACTIVE_COMPARATOR

Ibandronate

Intervention Type DRUG

To examine the efficacy of oral Ibandronate in osteoporosis

Oral Ibandronate and Vitamin D

Monthly oral intake of Ibandronate and daily oral intake of Vitamin D

Group Type ACTIVE_COMPARATOR

Oral Ibandronate and Vitamin D

Intervention Type DRUG

To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibandronate

To examine the efficacy of oral Ibandronate in osteoporosis

Intervention Type DRUG

Oral Ibandronate and Vitamin D

To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Osteoporotic patients who want to take oral ibandronate

Exclusion Criteria

* Patients who are allergic to oral ibandronate or vitamin D Patients who have not taken oral ibandronate for the last 2 years
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shinshu University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yukio Nakamura

Associate professor at Shinshu University

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yukio Nakamura

Matsumoto, Nagano, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yukio Nakamura, MD, PhD

Role: primary

+81-263-37-2659

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Oral IBN2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.